Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry

EuroIntervention 2014;10:591-599 published online ahead of print December 2013. DOI: 10.4244/EIJV10I5A102

Ralph Toelg
Ralph Toelg1*, MD, PhD; Béla Merkely2, MD, PhD; Andrejs Erglis3, MD, PhD; Stefan Hoffman4, MD; Huret Bruno5, MD; Ran Kornowski6, MD, PhD; Ton Slagboom7, MD; Christoph Naber8, MD, PhD; Bernhard Witzenbichler9, MD; Kristof Graf10, MD, PhD; Gert Richardt1, MD, PhD; Christoph Hehrlein11, MD, PhD; on behalf of the DELUX investigators
1. Herzzentrum Segeberger Kliniken GmbH, Bad Segeberg, Germany; 2. Semmelweis Egyetem, Budapest, Hungary; 3. P. Stadins Clinical University Hospital, Riga, Latvia; 4. Vivantes Klinikum im Friedrichshain, Berlin, Germany; 5. CHP Saint Martin, Caen, France;

Aims: Safety and efficacy of percutaneous coronary interventions using the Pantera Lux paclitaxel-coated balloon have been demonstrated in the PEPPER first-in-man trial. This prospective,

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bthccoronary artery diseasede novo lesionsdrug-coated balloonin-stent restenosispaclitaxel
Read next article
Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?

Latest news